Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events
Item 8.01 Other Events.
On November 15, 2016, Aclaris Therapeutics, Inc. (the Company)
issued a press release announcing top-line results from its Phase
3 clinical trial of A-101 for the treatment of seborrheic
keratosis, as well as information regarding a conference call to
discuss these results. The full text of the Companys press
release is filed as Exhibit99.1 to this Current Report on Form8-K
and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit |
|
|
Number |
ExhibitDescription |
|
99.1 |
Press Release, dated November 15, 2016, titled Aclaris |
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
